Yezan Munther Haddadin insider trades: Outlook Therapeutics (OTLK) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Yezan reports to the SEC
Open-market buys and sales
7 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | OTLK | ↑ Buy | 29,000 | $0.83 | $24K | Direct | Jun 3, 2026 (1d) |
| May 26, 2026 | OTLK | ↑ Buy | 34,000 | $0.44 | $15K | Direct | May 27, 2026 (1d) |
| Mar 28, 2024 | OTLK | ↑ Buy | 1,882 | $11.82 | $22K | Direct | Mar 29, 2024 (1d) |
| Oct 7, 2022 | OTLK | ↑ Buy | 33,343 | $1.29 | $43K | Direct | Oct 11, 2022 (4d) |
| Dec 2, 2021 | OTLK | ↑ Buy | 10,000 | $1.39 | $14K | Direct | Dec 2, 2021 (0d) |
| Apr 19, 2021 | OTLK | ↑ Buy | 10,000 | $1.82 | $18K | Direct | Apr 20, 2021 (1d) |
| Sep 22, 2020 | OTLK | ↑ Buy | 10,000 | $0.72 | $7K | Direct | Sep 22, 2020 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other OTLK insiders
Open-market trades in the last 12 months
About Yezan Munther Haddadin's insider trades
Yezan Munther Haddadin is a director at Outlook Therapeutics (OTLK). Since Sep 22, 2020, Yezan has reported 7 open-market purchases worth $144K and no sales on SEC Form 4. In the last 12 months: 2 buys ($39K).
Their filings also include grants and awards (15 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OTLK insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.